Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with <i>KRAS G12C</i> mutation
Jayesh Desai(Peter MacCallum Cancer Centre), Manish Patel(Sarah Cannon), Mark T. Lin(Princess Margaret Cancer Centre), Luis Paz-Arez(Hospital Universitario 12 De Octubre), Thomas B. Karasic(Hospital of the University of Pennsylvania), Erminia Massarelli(The University of Texas MD Anderson Cancer Center), Julie Chang(University of Wisconsin–Madison), Salvatore Siena(University of Milan), Jennifer L. Schutzman(Cancer Research Institute), Rasha Cosman(UNSW Sydney), Neekesh V. Dharia(Broad Institute), Adrian G. Sacher(Princess Margaret Cancer Centre), Laura Medina(Instituto de Investigación Biomédica de Málaga), Wilson H. Miller(Jewish General Hospital), Hans Prenen(Province of Antwerp), Sae‐Won Han(Seoul National University Hospital), Elena Garralda(Memorial Sloan Kettering Cancer Center), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stephanie Royer‐Joo(Princess Margaret Cancer Centre), Kenneth K. Yau(Roche (Canada)), Einat Shacham‐Shmueli(Sheba Medical Center), Eelke Gort(University Medical Center Utrecht), Martin Förster, Matthew Krebs(Christie's), Andrés Cervantes(INCLIVA Health Research Institute), Sandhya Mandlekar(University of Illinois Chicago), Jong‐Seok Lee(Seoul National University Bundang Hospital), Tae Won Kim(Asan Medical Center), Rafał Stec(Medical University of Warsaw), Yoonha Choi(Ewha Womans University), Alejandro Falcón(Princess Margaret Cancer Centre)
Cited by 10
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k